Skip to main content

April 2025

Crack GPAT — Prepare for GPAT Online 

Amneal Pharma Walk-In Drive at Baddi for Production Department - M.Pharm, B.Pharm, MSc Apply

Must be from Parenteral background & exposure to Aseptic vial, Bottle filling process is desirable. To be aware and responsible for achieving quality objective and fulfilling the requirements of applicable quality procedures. Sound technical knowledge of Aseptic area & Controlled area related activities.
Walk in Drive for M.Pharm, B.Pharm, MSc in QA, QC, Production at Biological E. Limited
As per the batch manufacturing procedures and packing protocols, samples such as in-process samples, finished product samples, stability samples, control samples, cleaning samples, and other samples should be collected and submitted
Walk in Drive for M.Pharm, B.Pharm, MSc in QA, QC, Microbiology at Aspiro Pharma
Having Injectable Experience of Analysis of raw material. In-process, Finish products, Stability testing, Process validation. Hands on Experience of HPLC, GC, LBPC, Osmometer, KF Auto titrator and UV - Visible spectrometer, LIMS,QMS,Participate in Lab incident , OOS, OOT, Analysis of deviation.
Require Pharmacovigilance Associate at ICON plc - B.Pharm, BSc Apply
Collecting and reviewing adverse event reports to ensure accurate and timely reporting in accordance with regulatory guidelines. Conducting signal detection and risk assessment activities to identify potential safety issues.
IQVIA looking for Medical Surveillance Specialist
Conduct preliminary review of laboratory results relative to established protocol-specific reference range guidelines, using relevant clinical laboratory experience and compares current results with prior laboratory values to evaluate or note clinically significant increases, decreases and contacts the investigator site for pertinent additional clinical contact for distribution to project team
Human Mixtard penfill to be replaced with injectables, Novo Nordisk clarifies
Novo Nordisk is now discontinuing its Human Mixtard penfill by the year's end. However Mixtard in India will continue to be available in vials. Along with it, other forms of insulin including human insulin from Novo Nordisk will continue to be available in vials & devices for patients across India.
Aclaris Therapeutics Secures U.S. Food and Drug Administration IND Clearance for ATI-052
Aclaris Therapeutics, Inc, a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for a Phase 1a/1b clinical trial of ATI-052, a potential best-in-class bispecific anti-TSLP/IL-4R monoclonal antibody.
A repurposed anti-inflammatory drug may help treat alcohol use disorder and related pain

A preclinical study from scientists at Scripps Research finds that a drug already FDA-approved for treating inflammatory conditions may help reduce both alcohol intake and pain sensitivity two issues that commonly co-occur with alcohol use disorder (AUD).

Empowering antibodies to better activate the immune system
Antibodies are best known for their ability to latch onto and neutralize bacteria, viruses and other pathogens. But these immune proteins can do more than that: They also activate other components of the immune system, which then go to work to clear an infection. A new study from Scripps Research explores the factors that influence how effectively antibodies engage specific immune cells.
National-Level Online Workshop on Ethical use of AI in Higher Education, Research & Productivity at Sardar Patel College of Pharmacy
This workshop is designed to empower faculty members, researchers, and postgraduate students with practical knowledge and skills for the ethical and effective use of Artificial Intelligence in academia and research. It offers comprehensive, hands-on training in utilizing advanced Al tools for literature review, research writing, manuscript development, data analysis, presentation, and responsible publishing practices.